Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial.
OBJECTIVES To compare the effect of a soy rich diet and hormone replacement therapy ( HRT ) on the main biomarkers of bone turnover and bone mineral density ( BMD ) at postmenopausal age . METHODS 187 healthy asymptomatic postmenopausal women , aged 39 - 60 , were recruited and r and omized into a soy rich diet group , a HRT group , and a control group .  Bone biomarkers and BMD were evaluated at baseline and after 6 months at the end of the study . RESULTS Diet is not as effective as HRT in reducing the postmenopausal turnover ; however diet stimulates bone osteoblastic activity , as evidence d by significant increase in osteocalcin concentrations . BMD decreases significantly only in the control group , but not in the intervention groups . CONCLUSIONS Our data suggest that soy products could be effective in reducing the risk of osteoporosis in asymptomatic postmenopausal women , but our findings should be confirmed before recommending the diet as a valid alternative to HRT
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .